Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva's Plan B One-Step Trips As Watson's Generic Gains Market Share

This article was originally published in The Tan Sheet

Executive Summary

Sales ofPlan B One-Step are taking a substantial hit from generic levonorgestrel despite the product's single-dose formulation and Teva Pharmaceutical Industries' aggressive marketing

You may also be interested in...



FDA Analysis Finds Plan B Safe For Children

FDA found only 13 reports of serious pediatric AERs following ingestion of original two-dose Plan B or one-dose Plan B One-Step. In a review released Jan. 27, Office of Surveillance and Epidemiology officials said the data do not causally link the majority of pediatric AERs definitively to the drug.

FDA Analysis Finds Plan B Safe For Children

FDA found only 13 reports of serious pediatric AERs following ingestion of original two-dose Plan B or one-dose Plan B One-Step. In a review released Jan. 27, Office of Surveillance and Epidemiology officials said the data do not causally link the majority of pediatric AERs definitively to the drug.

Teva's Plan B One-Step OTC Application Puts FDA On The Spot

Teva Pharmaceutical Industries asks FDA to allow over-the-counter sales of Plan B One-Step, starting the likely final leg of the emergency contraceptive's journey toward OTC status.

Related Content

Topics

UsernamePublicRestriction

Register

PS103830

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel